Using diet to counter the effects of multiple sclerosis
August 18, 2017
CNS Inflammatory Diseases Make Stem Cells Ineffective in Treating MS, Study Says
August 21, 2017
Show all

FDA clears hepatitis C drug Mavyret

Mavyret, from AbbVie, joins the market to treat hepatitis C.

The Food and Drug Administration has approved a new drug to treat adults with chronic hepatitis C virus genotypes 1-6. Mavyret, from AbbVie, was approved for HCV patients without cirrhosis or with mild cirrhosis, including patients with moderate to severe kidney disease and those on dialysis.

The FDA said that Mavyret is the first treatment of eight-week duration for all hepatitis C genotypes.

“This approval provides a shorter treatment duration for many patients, and also a treatment option for certain patients with genotype 1 infection, the most common HCV genotype in the United States, who were not successfully treated with other direct-acting antiviral treatments in the past,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.

AbbVie EVP research and development and chief scientific officer Dr. Michael Severino said, “The approval of Mavyret demonstrates AbbVie’s commitment to advancing science to help address unmet needs by delivering a new cure for patients who historically had limited treatment options.”

Read full article: FDA clears hepatitis C drug Mavyret – Drug Store News

Read Full Article: FDA clears hepatitis C drug Mavyret – Drug Store News 

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.